Mizuho Securities Sticks to Their Buy Rating for Amgen Inc


Mizuho Securities analyst Salim Syed maintained a Buy rating on Amgen Inc (NASDAQ: AMGN) today and set a price target of $200. The company’s shares closed yesterday at $185.99.

According to TipRanks.com, Syed is a 2-star analyst with an average return of 0.4% and a 51.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Spark Therapeutics, and Aerie Pharma.

Currently, the analyst consensus on Amgen Inc is Strong Buy and the average price target is $197.63, representing a 6.3% upside.

In a report issued on June 8, Oppenheimer also assigned a Buy rating to the stock with a $224 price target.

See today’s analyst top recommended stocks >>

Based on Amgen Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.59 billion and net profit of $2.31 billion. In comparison, last year the company earned revenue of $5.41 billion and had a net profit of $2.07 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts